Did you know that you can buy products from over 140 different suppliers from us?

SMAD, Mothers Against DPP Homolog 3 (SMAD3) (AA 417-425), (pSer423), (pSer425) antibody

Details for Product No. ABIN401332
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Antigen
Epitope
AA 417-425, pSer423, pSer425
(50), (37), (32), (31), (26), (23), (21), (12), (7), (6), (6), (5), (5), (4), (3), (3), (3), (3), (3), (3), (3), (2), (2), (2), (2), (2), (2), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
Reactivity
Cow (Bovine), Chicken, Human, Mouse (Murine), Pig (Porcine), Rat (Rattus), Xenopus laevis, Zebrafish (Danio rerio)
(332), (192), (183), (65), (52), (41), (15), (12), (4), (2), (2), (1), (1), (1), (1), (1), (1), (1)
Host
Rabbit
(309), (31)
Clonality
Polyclonal
Conjugate
Un-conjugated
(12), (11), (11), (7), (7), (7), (7), (7), (7), (7), (7), (4), (4), (4), (1)
Application
ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Western Blotting (WB)
(226), (150), (112), (82), (70), (38), (33), (11), (9), (9), (3), (2), (2), (1)
Pubmed 5 references available
Quantity 0.1 mg
Shipping to United States (Change)
Availability Discontinued
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Catalog No. ABIN401332
379.50 $
Plus shipping costs $45.00
Add to Basket

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen Synthetic peptide corresponding to amino acids 417-425 of Human SMAD3 protein
Isotype IgG
Specificity This affinity-purified antibody is directed against the phosphorylated form of Human Smad3 protein at the pSer423 and pSer425 residues. The product was affinity purified from monospecific antiserum by Immunoaffinity purification. Antiserum was first purified against the phosphorylated form of the immunizing peptide. The resultant affinity purified antibody was then cross adsorbed against the non-phosphorylated form of the immunizing peptide. Reactivity occurs against Human Smad3 pSer423 and pSer425 protein and the antibody is specific for the phosphorylated form of the protein. Reactivity with non-phosphorylated human Smad3 is minimal by ELISA and western blot. Expect reactivity against phosphorylated Smad1 and Smad5. Negligible reactivity is seen against other phosphorylated Smad family members.
Purification Immunoaffinity Chromatography.
Alternative Name SMAD3
Background Smad3 (also known as Mothers against decapentaplegic homolog 3 Mothers against DPP homolog 3, Mad3, hMAD-3, JV15-2 or hSMAD3) is a transcriptional modulator activated by TGF-beta (transforming growth factor) and activin type 1 receptor kinase. These activators exert diverse effects on a wide array of cellular processes. The Smad proteins mediate much of the signaling responses induced by the TGF-beta superfamily. Briefly, activated type I receptor phosphorylates receptor-activated Smads (R-Smads) at their c-terminal two extreme serines in the SSXS motif, e.g. Smad2 and Smad3 proteins in the TGF-beta pathway, or Smad1, Smad5 or Smad8 in the BMP pathway. Then the phosphorylated RSmad translocated into nucleus, where they regulate transcription of target genes. Based on microarray and animal model experiments, Smad3 accounts for at least 80% of all TGF-beta- mediated response.
Alternate names: JV15-2, MAD homolog 3, MAD-3, MADH3, Mad3, Mothers against DPP homolog 3, Mothers against decapentaplegic homolog 3, SMAD 3, SMAD family member 3, SMAD-3
Gene ID 4088
NCBI Accession NP_001138574.1
UniProt P84022
Research Area Signaling, Transcription Factors
Application Notes Suitable for use in ELISA, Immunohistochemistry and Western blot. Expect a bandapproximately 48 kDa in size corresponding to phosphorylated Smad3 protein by Westernblotting in the appropriate stimulated tissue or cell lysate or extract. Less than 0.2%reactivity is observed against the non-phosphorylated form of the immunizing peptide. This antibody is phospho specific for dual phosphorylated pS423 and pS425 of Smad3. Stimulation with 2 ng/ml TGF-beta for 1 hour is suggested. Recommended Dilutions: ELISA: 1/75,000-1/300,000. Western Blot: 1/2,000-1/20,000. Immunohistochemistry: 1/500. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions For Research Use only
Format Liquid
Concentration 1.0 mg/mL (by UV absorbance at 280 nm)
Buffer 0.02M Potassium Phosphate, 0.15M Sodium Chloride, pH 7.2 containing 0.01% (w/v) Sodium Azide as preservative.
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice Avoid repeated freezing and thawing.
Storage -20 °C
Expiry Date 12 months
Supplier Images
anti-SMAD, Mothers Against DPP Homolog 3 (SMAD3) (AA 417-425), (pSer423), (pSer425) antibody anti-SMAD, Mothers Against DPP Homolog 3 (SMAD3) (AA 417-425), (pSer423), (pSer425) antibody
anti-SMAD, Mothers Against DPP Homolog 3 (SMAD3) (AA 417-425), (pSer423), (pSer425) antibody (2) anti-SMAD, Mothers Against DPP Homolog 3 (SMAD3) (AA 417-425), (pSer423), (pSer425) antibody (Image 2)
Background publications Zhang, Feng, We et al.: "Receptor-associated Mad homologues synergize as effectors of the TGF-beta response." in: Nature, Vol. 383, Issue 6596, pp. 168-72, 1996 (PubMed).

Shi, Massagué: "Mechanisms of TGF-beta signaling from cell membrane to the nucleus." in: Cell, Vol. 113, Issue 6, pp. 685-700, 2003 (PubMed).

Derynck, Zhang: "Smad-dependent and Smad-independent pathways in TGF-beta family signalling." in: Nature, Vol. 425, Issue 6958, pp. 577-84, 2003 (PubMed).

Haynes: "Re: Thomas LC, et al. Pre-manipulative testing and the velocimeter. Manual Therapy (2007), doi:10:1016/j.math.2006.11.003." in: Manual therapy, Vol. 13, Issue 1, pp. e4; author reply e5-6, 2008 (PubMed).

Yamashita, Fatyol, Jin et al.: "TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta." in: Molecular cell, Vol. 31, Issue 6, pp. 918-24, 2008 (PubMed).

Validation Images
back to top